Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Taysha Gene Therapies, Inc. - Common Stock (NQ:TSHA)

5.040 +0.130 (+2.65%)
Streaming Delayed Price Updated: 9:52 AM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Taysha Gene Therapies, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
These stocks are gapping in today's session
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Monday. Let's explore the market movements and identify the stocks with significant gaps. 
Via Chartmill
Dow Gains Over 100 Points; NewGenIvf Group Shares Plummet
 
Via Benzinga
Topics Stocks
Earnings Scheduled For February 26, 2025
 
Via Benzinga
Assessing Taysha Gene Therapies: Insights From 8 Financial Analysts
 
Via Benzinga
Expert Outlook: Taysha Gene Therapies Through The Eyes Of 7 Analysts
 
Via Benzinga
Earnings Scheduled For November 13, 2024
 
Via Benzinga
Preview: Taysha Gene Therapies's Earnings
 
Via Benzinga
Peeling Back The Layers: Exploring Taysha Gene Therapies Through Analyst Insights
 
Via Benzinga
Hillenbrand Posts Better-Than-Expected Earnings, Joins Beazer Homes, Tapestry, Walt Disney And Other Big Stocks Moving Higher On Thursday
 
Via Benzinga
Advance Auto Parts Posts Weak Results, Joins Harrow, Taysha Gene Therapies And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
 
Via Benzinga
Neurogene Stock Plummets 44%: Is All Hope Lost for This Biotech?"
Neurogene has been on a huge run in 2024. That came to a halt after the company released trial results. But, the results may be better than the market thinks. 
Via MarketBeat
Why DLocal Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Where Taysha Gene Therapies Stands With Analysts
 
Via Benzinga
The Analyst Landscape: 16 Takes On Taysha Gene Therapies
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Dow Dips Over 200 Points; Home Depot Posts Upbeat Earnings
 
Via Benzinga
Topics Stocks
Tyson Foods Posts Better-Than-Expected Earnings, Joins Shopify, Sea, Buckle And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
Why Grab Holdings Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Breaking Down Taysha Gene Therapies: 16 Analysts Share Their Views
 
Via Benzinga
TSHA Stock Earnings: Taysha Gene Therapies Beats EPS, Misses Revenue for Q2 2024
TSHA stock results show that Taysha Gene Therapies beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Why Is Taysha Gene Therapies (TSHA) Stock Down 14% Today?
Taysha Gene Therapies stock is down on Wednesday after the company announced a proposed public offering for TSHA shares. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time to dive into the biggest pre-market stock movers as we check out all of the latest news happening on Wednesday morning! 
Via InvestorPlace
Worthington Enterprises Posts Downbeat Results, Joins Taysha Gene Therapies, General Mills And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
S&P 500 Edges Higher; America's Car-Mart Shares Tumble After Q4 Earnings
 
Via Benzinga
Topics Stocks
Why Quantum Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Crude Oil Rises 1%; DermTech Shares Plummet
 
Via Benzinga
What's Going On With Taysha Gene Therapies Stock Tuesday?
Taysha Gene Therapies reveals promising longer-term and initial clinical data from their REVEAL Phase 1/2 trials evaluating TSHA-102 for Rett syndrome. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.